[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premenopausal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premenopausal":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100651343","the-influence-of-plan-b-on-cardiovascular-health-100651343",false,"NCT07759635","The Influence of Plan B® on Cardiovascular Health.","The Influence of a Single Dose of Emergency Contraception on Markers of Venous Thrombosis and Vascular Function in Young, Healthy Females.","LEVOH","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. Pre-menopausal female.\n3. 18 - 35 years of age.\n4. Naturally cycling (i.e., not using any form of hormonal contraception for ≥ 3 months).\n5. Eumenorrheic (i.e., experiencing a predictable menstrual cycle lasting 21-45 days).\n6. In the surrounding Hamilton area, or able to visit McMaster for study visits.\n7. Not pregnant.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to the active substance levonorgestrel or to any ingredient in this formulation (i.e., levonorgestrel colloidal silicon dioxide, potato starch, magnesium stearate, talc, cornstarch, lactose monohydrate, or any ingredient\u002Fexcipient in the placebo capsule.\n2. Known or suspected pregnancy.\n3. At risk of the development of unwanted pregnancy within the past 72 hours.\n4. Known, suspected, or history of cardiovascular, metabolic, or musculoskeletal disease.\n5. Undiagnosed abnormal vaginal bleeding.\n6. Use of anti-HIV drugs, anticonvulsant drugs, antibiotics, rifampicin\u002Frifabutin, ulipristal acetate, Griseofulvin, Hypericum perforatum (St John's wort) or any other drug that may interfere with the normal pharmacokinetic or pharmacodynamic characteristics of the study intervention.\n7. Active or history of migraine.\n8. A condition or factor that would prevent the use of Plan B®.",true,"FEMALE","18 Years","35 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this double-blind randomized controlled trial is to learn about the impacts of a single dose of Plan B® on the cardiovascular system in young, health, premenopausal females. The main questions it aims to answer are:\n\n1. What is the short-term affect of Plan B® affect on the venous system?\n2. What is the short-term affect of Plan B® affect on the health of arteries?\n\nResearchers will compare a single dose of Plan B® (1.5 mg of levonorgestrel) to a placebo to see if Plan B® has unique effects on the cardiovascular system.\n\nParticipants will:\n\n1. Undergo baseline measurements of venous thrombosis markers, blood pressure, and measures of arterial function using ultrasound.\n2. Be randomized to either take a Plan B® or placebo pill\n3. Repeat baseline measurements of venous thrombosis markers, blood pressure, and measures of arterial function using ultrasound each hour, for 6-hours, and then 24- and 48- hours after taking the Plan B® or placebo pill.",[29,30],"Female","Premenopausal",[32,33,34,35],"Emergency contraceptives","Hormonal contraceptives","Venous thrombosis","Endothelial function","RECRUITING","2026-08-06",{"date":39,"type":40},"2026-08-12","ACTUAL",{"date":42,"type":23},"2026-07-22",{"date":44,"type":23},"2027-09-01",{"name":46,"class":47},"McMaster University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":48},"100650064","oxytocin-in-postmenopausal-women-100650064","NCT07742124","Oxytocin in Postmenopausal Women","Circulating Oxytocin and Its Clinical Correlates in Postmenopausal Women Compared With Premenopausal Controls - The OxyMENO Study","OxyMENO","Inclusion Criteria:\n\n* Female sex at birth\n* Age ≥18 years\n\nPremenopausal group:\n\n• Premenopausal women aged 18-35 years with regular menstrual cycles (21-35 days) for ≥3 months prior to study entry\n\nPostmenopausal group:\n\n• Postmenopausal women ≥2 years of postmenopause (i.e. 3 years since last menstrual period (LMP), with menopause defined as ≥ 12 months of amenorrhea)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Use of hormonal contraception or hormone replacement therapy within the last 3 months\n* Known endocrine disorders affecting the hypothalamic-pituitary-gonadal axis\n* Use of medications\n* Severe depression (BDI score \\> 28 points), any other severe psychiatric illness or acute medical disease\n* Inability to comply with study procedures\n* Participation in a trial with investigational drugs within the last 30 days",{"count":58,"type":23},30,"OBSERVATIONAL","The aim of the present study is to assess whether cumulative endogenous neurophysin I secretion over one month differs between premenopausal and postmenopausal women. Using repeated measurements of neurophysin-I (NP-I, equimolar surrogate marker of oxytocin) across defined physiological time points, this study investigates oxytocin system regulation under cyclic and non-cyclic hormonal conditions.\n\nThe primary hypothesis is that cumulative NP-I release, expressed as the area under the curve (AUC) is lower in the postmenopausal group compared to the premenopausal group.",[62,30],"Postmenopausal",[64,62,30,65,66,67],"Oxytocin","Neurophysin-I","cyclic hormonal condition","menstrual cyclic phase","NOT_YET_RECRUITING","2026-07-31",{"date":71,"type":40},"2026-08-03",{"date":73,"type":23},"2027-06-01",{"date":44,"type":23},{"name":76,"class":47},"University Hospital, Basel, Switzerland"]